)
Hyderabad-based biopharmaceutical company Suven Life Sciences Ltd (Suven) secured two product patents from New Zealand corresponding to new chemical entities (NCEs) for the treatment of disorders associated with neurodegenerative diseases.
These patents are valid through 2029 and 2030 respectively. The granted patents include the class of selective 5-HT compounds discovered by Suven and are being developed as therapeutic agents.
They are useful in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer’s disease, attention deficient hyperactivity disorder (ADHD), Huntington’s disease, Parkinson and schizophrenia.
With the new patents, Suven has a total of 19 patents from New Zealand. Products out of these inventions may be out-licensed at various phases of clinical development like at Phase-I or Phase-II, the company said.
